Välkommen till Via TT - det enkla pressverktyget

Nu finns en ny digital karta över kliniska prövningar i Europa. Kartan ger patienter och hälso- och sjukvårdspersonal enkel tillgång till aktuell information om pågående kliniska studier i närområde och underlättar därför tillgången till klinisk forskning inom EU.

The Phase III trial AV001 aims to evaluate QUTENZA® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical procedures[1], thus affecting more than 3 million people with surgical procedures per year in the U.S.[2] QUTENZA® is a topical system, non-systemic, non-opioid pain treatment that is currently approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults. Topline results are expected in Q4 2025 and Averitas Pharma aims to submit a supplemental new drug application (sNDA) for a US label extension in 2026, subject to positive data.

The launch in Germany through its step-down subsidiary betapharm marks Dr. Reddy's entry into digital therapeutics in Europe. Nerivio® is the first REN (wearable, FDA-cleared, and CE-marked for acute and/or prevention migraine (with or without aura) treatment for adults and adolescents (≥ 12 years). Nerivio® is worn on the upper arm during treatment and controlled by a smartphone app, making it comfortable and portable. Starting with Germany, followed by Spain and the UK, Dr. Reddy's plans to further increase access to Nerivio® in European countries.

Senast den 31 januari 2025 måste alla pågående kliniska prövningar i EU övergå till CTIS (Clinical Trials Information System), som är den gemensamma portalen och databasen för kliniska läkemedelsprövningar inom EU/EES. Då avslutas den treåriga övergångsperioden.

The merger will accelerate a new digitally-powered care management solution for chronic pain and beyond; Pharmaceutical company Grünenthal becomes the largest investor in the combined enterprise

Torsdag den 9 februari kl. 08.00 håller generaldirektörerna för de båda läkemedelsmyndigheterna pressträff om arbetet med ökat antal restanmälda läkemedel.

In cannabis trials against pain, people who take placebos report feeling largely the same level of pain relief as those who consume the active cannabinoid substance. Still, these studies receive significant media coverage regardless of the clinical outcome, report researchers from Karolinska Institutet in Sweden in a study published in JAMA Network Open.

I studier där cannabis testas för behandling av smärta ger placebo en betydande smärtlindring. Men cannabisstudierna får stort genomslag i media oavsett vilken effekt behandlingen har, visar forskare från Karolinska Institutet i en studie i JAMA Network Open.

Global Phase III programme to enable marketing authorisation in the EU, the US and Japan for an innovativenon-opioid investigational medicine. The programme will be conducted across approx. 200 study sites and include more than 1800 patients suffering from pain associated with osteoarthritis. Globally, more than 300 million patients suffer from osteoarthritis[1]. The global osteoarthritis market is expected to grow to approximately $11.0 billion in 2025[2]. Aachen, Germany – 18 August 2022 –Grünenthal announced today that the company has enrolled the first patient in its global clinical Phase III programme for resiniferatoxin (RTX). RTX is a highly potent Transient Receptor Potential Vanilloid 1 (TRPV1) agonist, with a well-validated mechanism of action. The discovery of TRPV1 was awarded the Nobel Prize of Physiology or Medicine in 2021. If approved, resiniferatoxin may provide patients with long-lasting pain relief with a favourable safety profile. Grünenthal’s Phase III programme wi

Patients with multiple sclerosis (MS) treated with the drug rituximab had a significantly lower risk of relapse compared with MS patients receiving standard treatment. This has been shown in a phase 3 clinical trial by researchers at Karolinska Institutet and Danderyd Hospital in Sweden published in The Lancet Neurology. Rituximab is not approved as an MS drug, but has proven to be effective in smaller studies and is therefore largely prescribed “off label”.

Idag börjar en ny gemensam EU-förordning för kliniska läkemedelsprövningar att gälla. De nya reglerna innebär bland annat ökad harmonisering av tillståndsprocessen inom EU och ökad öppenhet om beviljade prövningar.

Vinnova satsar på 11 innovationsmiljöer inom precisionshälsa som ska bana väg för en mer förebyggande, träffsäker och jämlik hälso- och sjukvård och bidra till att stärka Sverige som life science-nation. Innovationsmiljöerna handlar bland annat om utveckling för att motverka demens genom tidig upptäckt, individanpassad användning av antibiotika och att skapa en bättre beredskap för framtida pandemier.

Researchers at Karolinska Institutet in Sweden have developed, in collaboration with researchers in Germany and the U.S., new small antibodies, also known as nanobodies, which prevent the SARS-CoV-2 coronavirus from entering human cells. The research study, published in Science, shows that a combined nanobody had a particularly good effect – even if the virus mutated. According to the researchers, the nanobodies have the potential to be developed into a treatment for COVID-19.

The rheumatoid arthritis drug baricitinib can block viral entry and reduce mortality in patients with moderate to severe COVID-19, according to translational research by an international team coordinated by researchers from Karolinska Institutet in Sweden. The findings, published in the journal Science Advances, support the continuation of ongoing randomized clinical trials.

According to many observations, certain virus infections may play a part in the autoimmune attack that leads to type 1 diabetes. Researchers at Karolinska Institutet in Sweden and their Finnish colleagues have now produced a vaccine for these viruses in the hope that it could provide protection against the disease. The study is published today in the scientific journal Science Advances.

A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. This is the conclusion of a study in mice and human blood cells performed at Karolinska Institutet and SciLifeLab and published in the medical journal EMBO Molecular Medicine. The researchers will now launch a clinical study to test the new combination treatment in patients.

Children who have received radiotherapy for a brain tumour can develop cognitive problems later in life. In their studies on mice, researchers at Karolinska Institutet have now shown that the drug lithium can help to reverse the damage caused long after it has occurred. The study is published in the journal Molecular Psychiatry and the researchers are now planning to test the treatment in clinical trials.

[PRESS RELEASE, 3 SEPT 2015] Scientists at Karolinska Institutet and Karolinska University Hospital in Sweden have discovered a new explanation for severe early infant epilepsy. Mutations in the gene encoding the protein KCC2 can cause the disease, hereby confirming an earlier theory. The findings are being published in the journal Nature Communications.

[PRESS RELEASE, 23 MAY 2015] A novel study from Karolinska Institutet in Sweden suggests that RAS-antagonists, common drugs for patients with heart failure, may benefit also patients who have concomitant kidney disease, a group previously not studied. The findings are being presented today at the annual congress of European heart failure specialists in Seville, Spain.

New research shows that there are several effective strategies available to people wanting to avoid regaining weight after a successful diet. Anti-obesity drugs, meal replacements and a high protein diet can help weight loss maintenance, according to a meta-analysis published in the scientific periodical The American Journal of Clinical Nutrition.